V

Vanda Pharmaceuticals
D

VNDA

4.36500
USD
-0.14
(-3.00%)
مغلق
حجم التداول
0
الربح لكل سهم
-1
العائد الربحي
-
P/E
-13
حجم السوق
254,549,532
أصول ذات صلة
A
ALKS
-0.970
(-2.97%)
31.660 USD
AMGN
AMGN
4.42
(1.45%)
310.04 USD
BIIB
BIIB
-0.630
(-0.48%)
130.690 USD
BMRN
BMRN
-0.810
(-1.19%)
67.490 USD
GILD
GILD
0.450
(0.40%)
112.380 USD
INCY
INCY
0.180
(0.29%)
62.500 USD
REGN
REGN
-14.36
(-2.30%)
610.88 USD
المزيد
الأخبار المقالات

العنوان: Vanda Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.